If you’re using imaging to manage glioblastoma (GBM) and looking for an artificial intelligence (AI) solution, you’ll be interested in this latest success story from NCI’s Small Business Innovation Research program. It could help make your AI-guided GBM segmentation easier.

With support from NCI’s SBIR program, which helps small businesses with research and development, a new cyber device (called “i2Contour”) recently received clearance from the U.S. Food and Drug Administration. The tool, developed by MRIMath, LLC, of Birmingham, AL, gives you an interpretable, physician-in-the-loop, AI-aided approach for measuring and labeling GBM.

According to company co-founder, Dr. Hassan Fathallah-Shaykh, i2Contour’s interactive user interface can help you accurately outline tumors, visualize AI's explanations and volumetric measurements, and review analysis results.

He added, “Using this approach allows you not only to comply with federal standards for managing medical data but is easily incorporated into clinical workflows so you can collaborate, plan, and monitor treatment tailored to each patient.”

Said Dr. Fathallah-Shaykh, “Our goal with this tool is to assist physicians in producing accurate tumor segmentation and volumetric analysis within minutes. It’s the first in what we hope will be a full suite of AI models to support research and care in the cancer and neuroscience fields.”